Cantor Fitzgerald Maintains Overweight on Apellis Pharmaceuticals, Lowers Price Target to $31

Benzinga Newsdesk www.benzinga.com Negative 87.7%

Neg 87.7% Neu 0% Pos 0%

Cantor Fitzgerald analyst Steve Seedhouse maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Overweight and lowers the price target from $35 to $31.